Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure☆
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Congestive heart failure (CHF) is a common cause of atrial fibrillation (AF). Oxidative stress and inflammation (profibrotic) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha, antifibrotic) factors may be involved in CHF-related remodeling. We evaluated the effects of simvastatin (antioxidant, anti-inflammatory) and fenofibrate (PPAR-alpha activator) on CHF-related atrial remodeling. METHODS AND RESULTS: Dogs were subjected to 2-week ventricular tachypacing (VTP) in the absence and presence of simvastatin (20 or 80 mg/day) or fenofibrate. Induced AF duration (DAF) was increased by VTP from 36+/-14 (non-paced controls) to 1005+/-257 s (p<0.01). Simvastatin prevented VTP-induced DAF increases (147+/-37 and 84+/-37 s at 20 and 80 mg/day, respectively), but fenofibrate did not (1018+/-352 s). Simvastatin also attenuated CHF-induced conduction abnormalities (heterogeneity-index reduced from 1.5+/-0.1 to 1.1+/-0.1 and 1.0+/-0.1 at 20 and 80 mg/day, p<0.01) and atrial fibrosis (from 19.4+/-1.3% to 10.8+/-0.8% and 9.9+/-0.8% at 20 and 80 mg/day, p<0.01), while fenofibrate did not. Simvastatin (but not fenofibrate) also attenuated VTP-induced left-ventricular nitric-oxide synthase and nitrotyrosine increases, along with hemodynamic dysfunction. Atrial fibroblast proliferation increased with 24-h fetal bovine serum (FBS) stimulation from 654+/-153 to 7264+/-1636 DPM (p<0.001). Simvastatin, but not fenofibrate, suppressed fibroblast proliferation (664+/-192 DPM, p<0.001). Simvastatin also significantly attenuated transforming growth factor-beta1-stimulated alpha-smooth muscle actin (alpha-SMA) expression (indicating myofibroblast differentiation) from 1.3+/-0.1 to 1.0+/-0.1 times baseline (p<0.05). CONCLUSIONS: CHF-induced atrial structural remodeling and AF promotion are attenuated by simvastatin, but not fenofibrate. Statin-induced inhibition of profibrotic atrial fibroblast responses and attenuation of left-ventricular dysfunction may contribute to preventing the CHF-induced fibrotic AF substrate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We chose fenofibrate concentration based on concentrations in previous in vitro studies [26,27], which were comparable to concentrations achieved clinically [28].”
Inflammation as a risk factor for atrial fibrillation
Aviles, R. J., Martin, D. O., Apperson-Hansen, C., Houghtaling, P. L., Rautaharju, P., Kronmal, R. A., Tracy, R. P., Van Wagoner, D. R., Psaty, B. M., Lauer, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103131.70301.4f · Cited by 1,425 · cited 1×
“Recent evidence suggests the possible involvement of oxidative stress [4,5] and inflammation [6,7] in the pathogenesis of CHF and AF.”
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345 · cited 2×
“We elected to compare simvastatin to fenofibrate because both are lipid-lowering drugs and PPAR-αagonists like fenofibrate also have pleiotropic antiinflammation and antiproliferative effects [ 13 ,14] .O ur results showthatdespitesomesimilarities,statinsandPPAR-αagonists have very different efficacy in preventing CHF…”
BackgroundWachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826 · cited 1×
“Clinical studies suggest that ACE inhibition prevents AF in patients with left ventricular dysfunction [36,37] and hypertension [38,39].”
Goette, A., Staack, T., Röcken, C., Arndt, M., Geller, J. C., Huth, C., Ansorge, S., Klein, H. U., & Lendeckel, U. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00611-2 · Cited by 583 · cited 1×
“reported that AT1 receptors are downregulated, and AT2 receptors upregulated, in AF patients [32].”
Watanabe, K., Fujii, H., Takahashi, T., Kodama, M., Aizawa, Y., Ohta, Y., Ono, T., Hasegawa, G., Naito, M., Nakajima, T., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000248200 · Cited by 314
Diep, Q. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.11.004 · Cited by 165 · cited 1×
“The PPARα activator, fenofibrate, inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats [15] and diastolic dysfunction in hypertensive rats [16].”
PORTER, K., TURNER, N., OREGAN, D., & BALL, S. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.07.020 · Cited by 123
Cited by
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal
Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00031.2009 · Cited by 1,273
Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
Burstein, B., & Nattel, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.064 · Cited by 1,242
Self-citationAtrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Nattel, S., Burstein, B., & Dobrev, D. (2008) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.107.754564 · Cited by 1,124
Self-citationCardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Atrial Fibrillation Pathophysiology: Implications for Management
Iwasaki, Y.-K., Nishida, K., Kato, T., & Nattel, S. (2011) · Circulation · doi:10.1161/circulationaha.111.019893 · Cited by 852
Self-citation
Metadata
- Authors
- SHIROSHITATAKESHITA, A., BRUNDEL, B., BURSTEIN, B., LEUNG, T., MITAMURA, H., OGAWA, S., & NATTEL, S.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04-01
- Volume
- 74
- Issue
- 1
- Pages
- 75-84
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2149372808
- Cited by
- 149
- References
- 8
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure☆. https://app.cochat.ai/papers/10.1016/j.cardiores.2007.01.002
- The paper
- SHIROSHITATAKESHITA, A., BRUNDEL, B., BURSTEIN, B., LEUNG, T., MITAMURA, H., OGAWA, S., & NATTEL, S. (2007). Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure☆. Cardiovascular Research. https://doi.org/10.1016/j.cardiores.2007.01.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.